Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Director/PDMR Shareholding

7 Sep 2011 16:15

RNS Number : 8287N
Evolution Group PLC
07 September 2011
 



The Evolution Group Plc

 

7 September 2011

 

The Evolution Group Plc

Directors' Shareholdings

 

 

The Evolution Group Plc ("Evolution" or the "Company"), the listed investment bank and private client investment management group, announces that Capita Share Plan Services (the "Trustee") in its capacity as the trustee of The Evolution Group Plc Employee Share Incentive Plan Trust (the "Plan"), had on 6 September 2011 purchased 26,056 Ordinary Shares of 1p each in the Company ("Partnership Shares") at a price of 92 pence per share. Evolution had today allotted 26,056 Ordinary Shares of 1p each credited as fully paid at 92 pence per share to the Trustee as "matching shares" under the terms of the Plan.

 

The Trustee holds the shares as Nominee for the participants of the Plan.

 

The total purchase and issue for the Plan included the following shares in respect of the following directors:

 

 

Name of Director

Number of Ordinary shares (including partnership and matching shares) acquired by the Trustee for director

 

 

 

Total number of Ordinary shares held by the Trustee for director following such acquisition

Interest of director in Ordinary shares including the shares held by the Trustee for the director ("Total Interest")

 

Percentage of issued share capital represented by director's Total Interest

Alex Snow

272

26,303

5,634,545

2.422%

Philip Howell

272

5,839

5,839

0.003%

 

 

The above directors' interests exclude any interests in options over ordinary shares in the Company.

 

 

 

 

For more information please contact:

The Evolution Group Plc

Tony Lee, Group Company Secretary Tel: 020 7071 4300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEDLFBFKFFBBL
Date   Source Headline
25th Apr 20243:46 pmRNSChange of Name
22nd Apr 202410:11 amRNSHolding(s) in Company
11th Apr 20243:04 pmRNSHolding(s) in Company
9th Apr 20247:00 amRNSHolding(s) in Company
8th Apr 20244:03 pmRNSHolding(s) in Company
5th Apr 20243:39 pmRNSDirector/PDMR Shareholding
5th Apr 20242:40 pmRNSHolding(s) in Company
4th Apr 20241:59 pmRNSResult of General Meeting
4th Apr 20247:00 amRNSResult of Retail Offer
19th Mar 20245:03 pmRNSRetail Offer
19th Mar 20245:00 pmRNSAcquisition, Fundraising and Change of Name
27th Feb 20247:00 amRNSSFX-01 positive update in bowel cancer models
19th Feb 202411:22 amRNSPositive update on SFX-01 in vitro GBM studies
9th Feb 202411:01 amRNSNotice of Dispute lodged with Stalicla SA
16th Jan 20243:07 pmRNSSeries B Fund Raise by partner, Stalicla SA
29th Dec 202311:29 amRNSHolding(s) in Company
22nd Dec 20237:00 amRNSDirectorate Changes
13th Nov 20237:00 amRNSUpcoming conferences
31st Oct 20237:00 amRNSHalf-year Report
26th Oct 20237:00 amRNSErasmus Medical Center begins glioblastoma studies
19th Oct 20232:26 pmRNSAuthored Article Publication
5th Sep 20237:00 amRNSDirectorate Changes
15th Aug 20237:00 amRNSFinal Report from Phase 1b PK/PD study
3rd Aug 202312:38 pmRNSRule 17 Disclosure
2nd Aug 20237:00 amRNSReturn of rights to Sulforadex from Juvenescence
21st Jul 202312:02 pmRNSResult of AGM
27th Jun 20237:00 amRNSSFX-01 radiosensitisation effect confirmed in-vivo
20th Jun 20231:59 pmRNSNotice of AGM & Posting of Annual Report
19th Jun 20237:00 amRNSGrant Success for Glioblastoma studies
7th Jun 20237:00 amRNSFinal Results
26th May 202311:00 amRNSNotice of Results
22nd Mar 20237:00 amRNSPreliminary results from Phase 1b study
16th Mar 20232:00 pmRNSPrice Monitoring Extension
16th Mar 202311:05 amRNSSecond Price Monitoring Extn
16th Mar 202311:00 amRNSPrice Monitoring Extension
16th Mar 20237:00 amRNSFurther evidence of radiosensitisation by SFX-01
13th Mar 20237:00 amRNSNo exposure to Silicon Valley Bank
25th Jan 20237:00 amRNSClinical trial update
14th Dec 20225:08 pmRNSGrant of Options - Director/PDMR Shareholding
12th Dec 202211:54 amEQSEvgen Pharma 'cash runway in pretty good shape'
8th Dec 20227:00 amRNSHalf-year Report
2nd Dec 20227:00 amRNSNotice of Half Year Results
30th Nov 20222:06 pmRNSSecond Price Monitoring Extn
30th Nov 20222:00 pmRNSPrice Monitoring Extension
16th Nov 20227:00 amRNSStudy started of new SFX-01 tablet formulation
21st Oct 202211:05 amRNSSecond Price Monitoring Extn
21st Oct 202211:00 amRNSPrice Monitoring Extension
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 20227:00 amRNSClinical trial update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.